<DOC>
	<DOCNO>NCT00663689</DOCNO>
	<brief_summary>This non-randomized open-label uncontrolled phase II trial evaluate efficacy toxicity erlotinib patient asymptomatic brain metastasis advance NSCLC benefit first line chemotherapy . Patients stage IV NSCLC one asymptomatic brain metastasis benefit first line chemotherapy receive oral erlotinib 150mg daily disease progression unacceptable toxicity . These patient ' direct DNA sequence tumor tissue EGFR exons 18-21 analyze The response evaluate RECIST criterion patient receive erlotinib 6 weeks.If patient present progress disease brain metastasis therapy erlotinib , patient receive irradiation brain metastasis.If response stable disease , partial response complete response , examine brain MRI every 12 week .</brief_summary>
	<brief_title>Efficacy Erlotinib Brain Metastasis Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : 1 . Histological cytological document stage IV NSCLC . Sputum cytology alone exclude 2 . Extracerebral lesion show stable disease first line chemotherapy . Patient recover CTCAE grade 3/4 toxicity . Patients never receive EGFRTKI EGFR monoclonal antibody . 3 . Patients must least 18 year . 4 . ECOG Performance Status 0 , 1 2 . 5 . Life expectancy least 12 week . 6 . Appraisable disease , presence least three lesion longest diameter &lt; 10 mm brain MRI . 7 . Haemoglobin ³ 10.0 g/dl , Absolute neutrophil count ( ANC ) ³1.5 x 109/L , platelet ³ 100 x 109/L . 8 . Total bilirubin £ 1.5 x upper limit normal ( ULN ) 9 . ALT AST &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . 10 . Creatinine clearance ³ 60ml/min ( calculate accord Cockcroftgault formula ) . 11 . PTINR/PTT &lt; 1.2 x ULN . 12 . Written informed consent . 13 . Able comply study followup procedure . Exclusion criterion : 1 . Mixed small cell nonsmall cell lung cancer histology . 2 . Any unresolved toxicity &gt; CTCAE grade 2 previous anticancer therapy . 3 . Patients exposure biotherapy , immunotherapy within 4 week study entry . 4 . Other concurrent anticancer therapy . 5 . Patients exposure investigational drug therapy outside trial . 6 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . 7 . Any unstable systemic disease ( include active infection , hepatic , renal , metabolic disease seizure disorder require medication ) . 8 . Significant cardiovascular event : congestive heart failure &gt; NYHA class 2 ; unstable angina , active CAD ( myocardial infarction 1 year prior study entry allow ) ; serious cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 9 . Brain metastasis spinal cord compression , treat start study treatment , symptom . Symptoms include sign increase intracranial pressure , headache , nausea vomiting , cognitive affective disturbance , seizure , focal neurologic symptom . 10 . History another malignancy within last 5 year except cured carcinoma insitu uterine cervix , cure basal cell carcinoma skin superficial bladder tumor [ Ta , Tis &amp; T1 ] . 11 . Pregnant breastfeed woman . 12 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . 13 . Any condition unstable could jeopardize safety patient compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>erlotinib</keyword>
</DOC>